Fundraising FoxBiotech Startups
11,050 companies tagged Biotech, with their investors and founders.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
Anidyn develops Onco4D, a technology used to predict cancer patients' response to chemotherapy, with reported clinical results showing a 97% negative predictive value for pathologic complete response in breast cancer patients. The company operates in oncology diagnostics.
0 investors
Animerra develops next-generation biologics for companion animal health, applying therapeutic innovation from human medicine to veterinary treatment. The company targets pet owners and veterinary markets with innovative protein-based therapeutics and biologics treatments.
0 investors
Anivive develops new medicines for companion animals, using software across the drug development process to accelerate the creation of treatments. It serves the animal health community, focusing on veterinary and pet health pharmaceuticals.
0 investors
Ankasa is developing ART352-L, a regenerative medicine designed to enhance bone formation in reconstructive surgeries, with initial focus on spinal fusion procedures to treat degenerative disc disease. The therapy aims to improve healing outcomes and reduce revision surgeries for patients requiring bone reconstruction.
0 investors
0 investors
0 investors
0 investors
Antidote Therapeutics is a biotechnology company focused on drug discovery and development, led by an experienced team with backgrounds in clinical trials, pharmaceutical development, and biomarker-driven innovation.
0 investors
0 investors
Antlia Bioscience develops long-acting therapeutics aimed at treating chronic cardiometabolic diseases.
0 investors
AnTolRx develops immunotherapy therapeutics based on research in immune tolerance, targeting immune-mediated disorders. The company is led by scientists and industry veterans with expertise in drug development and biotechnology commercialization.
0 investors
0 investors
0 investors
0 investors
Apertor develops a class of therapeutics called Interceptors that selectively disrupt disease-causing protein-protein interactions through proximity induction, recruiting an abundant protein found in cancer cells to block the interactions. The company uses a synthetic biology platform to build a pipeline of cancer treatments.
0 investors
0 investors
0 investors
0 investors